Pricing Log in Create free account
Monday 9 November 2026 Export NBIX’s income statement to Excel — free account

Neurocrine Biosciences, Inc.

NBIX

Healthcare Drug Manufacturers Specialty & Generic

Neurocrine Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 billion, up 21.4% from fiscal 2024.

Revenue
+41.2%
EPS
−3.67%
Free cash flow
+79.0%

Quarter to September 2026, against a year earlier

169.00 4.37 +2.65%
Market cap
$16.7B
P/E
24.2×
Fwd P/E
22.5×
Dividend yield
—
F-score
7/9
ROIC
17.7%
Net debt / EBITDA
−2.3×
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Neurocrine Biosciences, Inc. (NBIX) EV/Sales

Alert me on EV/Sales

As of 9 November 2026, Neurocrine Biosciences, Inc. (NBIX) trades at a EV/Sales of 4.6×. Over the past ten years it has ranged from 0.0× (March 2015) to 208× (November 2015); the current reading is higher than 7% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 2.8× and above the Healthcare sector median of 3.6×.

EV/Sales, daily

Embed this chart

Annual newest first

Period EV/Sales Change
FY2025 4.6× (17.64%)
FY2024 5.6× (14.77%)
FY2023 6.6× (11.07%)
FY2022 7.4× 3.78%
FY2021 7.1× (15.67%)
FY2020 8.4× (31.07%)
FY2019 12.2× (15.84%)
FY2018 14.5× (62.44%)
FY2017 38.7× (53.94%)
FY2016 84.1× (58.07%)

Quarterly newest first

Period EV/Sales Change
Sep 2026 3.8× (24.55%)
Jun 2026 5.1× 26.66%
Mar 2026 4.0× (12.75%)
Dec 2025 4.6× (7.67%)
36 more quarters

Against its own ten years

Low 0.0× High 208×
Ten-year median 8.6×
Current reading's percentile 6

EV/Sales against peers

Company EV/Sales
VTRS Viatris Inc. compare 2.4×
AMRX AMNEAL PHARMACEUTICALS, INC. compare 3.2×
ELAN Elanco Animal Health Incorporated compare 3.3×
RDY Dr. Reddy's Laboratories Ltd compare 3.7×
ZTS Zoetis Inc. compare 4.4×
NBIX Neurocrine Biosciences, Inc. 4.6×
ALKS Alkermes plc compare 4.9×
UTHR United Therapeutics Corporation compare 7.3×
KNSA Kiniksa Pharmaceuticals International, plc compare 7.6×
Drug Manufacturers Specialty & Generic industry median 2.8×
Healthcare sector median 3.6×
Market median 2.1×

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on NBIX